A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additional biosimilar candidates in Europe.

in 2012 and J&J’s Simponi (golimumab) in 2013. In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors ...

Objective To evaluate radiographic progression in patients with ankylosing spondylitis (AS) receiving two different doses of the tumour necrosis factor antagonist golimumab. Methods 356 patients with ...

Golimumab is given once every four weeks, subcutaneously, and also has an intravenous formulation. These intervals are changed, at times, with some of these agents, related to patient response. For ...

In patients with inadequate remission or low disease activity, advanced therapies are indicated, including targeted synthetic DMARDs, such as biologic agents (tumor necrosis factor-alpha [TNFα] ...

These anti-TNF agents – including infliximab, etanercept, adalimumab, golimumab and certolizumab – improve mobility while alleviating pain. The anti-TNF medications are given either by self-injection ...

Multifocal cutaneous leishmaniasis in a patient treated with golimumab for psoriatic arthritis Veronica Forte 1, Anna Silvia Biamonte 2, Massimo Menichini 3, Fabrizio Liberati 1, Luca Ventura 1 ...

Leishmaniasis is a zoonosis caused by protozoans transmitted by sandflies. Immunosuppression is a risk factor for developing leishmaniasis in patients treated with TNF inhibitors for autoimmune ...